drugset / Trial / NCT04149015
Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a single center, phase II study, to evaluate the effectiveness and safety of POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the neoadjuvant therapy for patients with advanced/metastatic gastric cancer.
Timeline
- Start
- 2019-11
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |